Business
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their last visit in the Company's first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to annou
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"- STAR-1 topline results expected by the end of March 2025 -","length":60,"tagName":"p","attribs":{}},{"type":"text","content":"- Over 30 million acne patients seek treatment in the U.S. each year -","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"- XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America -","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, March 4, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their last visit in the Company's first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to announce topline data by the end of March 2025.","length":612,"tagName":"p"},{"type":"image","alt":"Dermata Logo","displaySize":"","headline":null,"caption":"Dermata Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":309,"url":"https://media.zenfs.com/en/prnewswire.com/37bc5858095bf0fda616c1d1313024ad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N5v3qQ88yzN2xdRf1AFURw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/37bc5858095bf0fda616c1d1313024ad","width":400,"height":309}},"href":"https://mma.prnewswire.com/media/2632577/Dermata_Light_Blue_White_Letters_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We wish to thank the patients and investigators for their time and commitment to this study. Their efforts helped keep this pivotal Phase 3 trial on schedule. We could not have completed this study without their contribution," commented Christopher Nardo, Ph.D., Dermata's Chief Development Officer. "Throughout the conduct of the study, we have had great interest from our clinical sites, investigators, and study participants as we develop XYNGARI™, which could potentially change how acne is treated. With the last patient visit behind us, we can focus our efforts on cleaning and locking the database, ...